EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Correlation between PD-L1 expression and clinical pathology, immunobiological markers, and prognosis in gastroenteropancreatic neuroendocrine neoplasms: a systematic review and meta-analysis

Qiming Zheng, Shangbo Jin, Xinyue Xie, Qingjun Guo, Chiyi Chen, Wentao Jiang

Frontiers in Immunology · 2026

DOI: 10.3389/fimmu.2026.1772011 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Immunology, 2026. Verfasst von Qiming Zheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery/Transplantation, First Central Hospital of Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Pancreatic Neoplasms, Neuroendocrine Tumors, Intestinal Neoplasms. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have limited therapeutic options. The role of programmed death-ligand 1 (PD-L1) in their clinicopathology, immune markers, and prognosis remains controversial. This meta-analysis aimed to systematically clarify these relationships.

Methods

We searched Medline/PubMed, Web of Science, Embase, and Cochrane Library from inception to November 2025 for studies on PD-L1 expression in GEP-NENs. Two researchers independently extracted data and assessed quality via Newcastle-Ottawa Scale (NOS). Pooled analyses were conducted using Stata 17.0, with odds ratio (OR)/hazard ratio (HR) and 95% confidence interval (CI) as effect indicators, and fixed/random-effects models chosen by heterogeneity.

Results

A total of 22 studies involving 1,872 patients (17 high-quality and 5 moderate-quality) were included. High PD-L1 expression was significantly associated with higher tumor grade (OR = 3.78, 95% CI:2.04-7.01; p<0.001), poorer differentiation (OR = 2.80, 95% CI:1.18-6.65; p=0.020), increased PD-1 expression (OR = 4.15, 95% CI:2.16-7.99; p<0.001), and shorter overall survival (HR = 1.66, 95% CI:1.32-2.10; p<0.001). No significant associations were found with sex, age, histological type, tumor stage, invasion, metastasis, CD8+ T cell/FOXP3+ T cell infiltration, or mismatch repair (MMR) status. No publication bias existed.

Conclusion

High PD-L1 expression in GEP-NENs correlates with aggressive clinicopathological features, PD-1 upregulation, and unfavorable prognosis. PD-L1 may serve as a prognostic biomarker and therapeutic target for immune checkpoint inhibitors, particularly in high-grade/poorly differentiated tumors. Large-scale prospective studies are needed for validation. Systematic review registration https://www.crd.york.ac.uk/PROSPERO , identifier CRD420251048602.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenPancreatic NeoplasmsNeuroendocrine TumorsIntestinal NeoplasmsBiomarkers, TumorStomach NeoplasmsHumansPrognosis

Stichwörter der Autor:innen

gastroenteropancreaticimmunotherapyneuroendocrine neoplasmsprognosisprogrammed cell death ligand 1

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of General Surgery/Transplantation, First Central Hospital of Tianjin Medical University, Tianjin, China.
  • Department of Liver Transplantation, Tianjin First Central Hospital, Tianjin, China.
  • Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin First Center Hospital, Tianjin, China.
  • Tianjin Key Laboratory for Organ Transplantation, Tianjin First Center Hospital, Tianjin, China.
  • Department of Hepatobiliary Pancreatic Spleen Surgery, Baoji People's Hospital, Baoji, Shaanxi, China.
  • Institute of Transplantation Medicine, Nankai University, Tianjin, China.

Zitieren

APA

Zheng, Q., Jin, S., Xie, X., Guo, Q., Chen, C., & Jiang, W. (2026). Correlation between PD-L1 expression and clinical pathology, immunobiological markers, and prognosis in gastroenteropancreatic neuroendocrine neoplasms: a systematic review and meta-analysis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1772011

Vancouver

Zheng Q, Jin S, Xie X, Guo Q, Chen C, Jiang W. Correlation between PD-L1 expression and clinical pathology, immunobiological markers, and prognosis in gastroenteropancreatic neuroendocrine neoplasms: a systematic review and meta-analysis. Frontiers in Immunology. 2026. doi:10.3389/fimmu.2026.1772011

BibTeX
@article{Zheng2026,
  author = {Zheng, Qiming and Jin, Shangbo and Xie, Xinyue and Guo, Qingjun and Chen, Chiyi and Jiang, Wentao},
  title = {Correlation between PD-L1 expression and clinical pathology, immunobiological markers, and prognosis in gastroenteropancreatic neuroendocrine neoplasms: a systematic review and meta-analysis},
  journal = {Frontiers in Immunology},
  year = {2026},
  doi = {10.3389/fimmu.2026.1772011}
}
Kostenlos starten →